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Background: The adjunctive use of matrix metalloproteinase
(MMP) inhibitors with scaling and root planing (SRP) promotes
new attachment in patients with periodontal disease. This pilot
study was designed to examine aspects of the biological
response brought about by the MMP inhibitor low dose doxycy-
cline (LDD) combined with access flap surgery (AFS) on the
modulation of periodontal wound repair in patients with severe
chronic periodontitis.
Methods: Twenty-four subjects were enrolled into a 12-month,
randomized, placebo-controlled, double-masked trial to evalu-
ate clinical, biochemical, and microbial measures of disease in
response to 6 months therapy of either placebo capsules + AFS
or LDD (20 mg b.i.d.) + AFS. Clinical measures including prob-
ing depth (PD), clinical attachment levels (CAL), and bleeding
on probing (BOP) as well as gingival crevicular fluid bone marker
assessment (ICTP) and microbial DNA analysis (levels and pro-
portions of 40 bacterial species) were performed at baseline
and 3, 6, 9, and 12 months.
Results: Patients treated with LDD + AFS showed more potent
reductions in PD in surgically treated sites of >6 mm (P <0.05,
12 months). Furthermore, LDD + AFS resulted in greater reduc-
tions in ICTP levels compared to placebo + AFS. Rebounds in
ICTP levels were noted when the drug was withdrawn. No statis-
tical differences between the groups in mean counts were found
for any pathogen tested.
Conclusions: This pilot study suggests that LDD in combi-
nation with AFS may improve the response of surgical therapy
in reducing probing depth in severe chronic periodontal disease.
LDD administration also tends to reduce local periodontal bone
resorption during drug administration. The use of LDD did not
appear to contribute to any significant shifts in the microbiota
beyond that of surgery alone. J Periodontol 2004;75:441-452.
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A
lthough periodontitis is initiated by
subgingival microbiota, it is gener-
ally accepted that mediators of
connective tissue breakdown are gener-
ated to a large extent by the host’s res-
ponse to the pathogenic infection.1 In a
susceptible host, microbial virulence fac-
tors trigger the release of host-derived
enzymes such as proteases (e.g., matrix
metalloproteinases [MMPs]) which can lead
to periodontal tissue destruction.2-4 Colla-
genases, a subclass of the MMP family, are
a group of enzymes capable of disrupting
the triple helix of type I collagen in phys-
iological conditions, the primary structural
component of the periodontium. Elevated
levels of collagenases and other host-
derived proteinases (e.g., cathepsins, elas-
tase, tryptases/trypsin like proteinases)
have been detected in inflamed gingiva,
gingival crevicular fluid (GCF), and saliva
of humans with periodontal disease.5-7
Studies have shown that tetracyclines
(including the semi-synthetic analogues
minocycline and doxycycline) are capa-
ble of inhibiting mammalian collagenase
activity.8,9 Tetracycline’s inhibitory effect
on collagenases appears to occur through
the drug’s ability to bind to zinc cations
as well as calcium ions in the catalytic
domain of the MMP molecule.10,11 In fact,
tetracycline also inhibits another class of
Ca++ dependent metalloproteinases termed
gelatinases (or type IV collagenases)12
and prevents the degradation of a serum
protein called α1-proteinase inhibitor (or
α1-antitrypsin).
13 Furthermore, adminis-
tration of low doses of doxycycline (LDD;
a tetracycline analog) given 20 mg b.i.d.
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rather than the 50 or 100 mg capsules, typically admin-
istered as commercially available antibiotics, effectively
inhibit collagenase activity in the gingival tissues as
well as in GCF14 without exerting direct effects on the
subgingival microorganisms.
Investigations have demonstrated the efficacy of
LDD therapy on promoting probing depth (PD) reduc-
tion and clinical attachment level (CAL) gains when
combined with scaling and root planing (SRP) therapy
in chronic periodontitis patients.15,16 Caton and co-
workers, in a multi-center clinical trial, found that a
9-month regimen of LDD + SRP provided statistically
significant improvements in CAL, PD, and bleeding on
probing (BOP) over a 9-month period compared to
placebo + SRP in periodontitis patients.17
Many of the crucial cellular responses of early post-
surgical wound healing, such as inflammatory infiltra-
tion, angiogenesis, and reepithelialization, are made
possible through the action of MMPs.18 In addition, the
amount and organization of normal wound extracellu-
lar matrix are determined by a dynamic balance among
overall matrix synthesis, deposition, and degrada-
tion.19,20 Expression of MMPs such as collagenases
and gelatinases are elevated in acute wounds and still
greater levels are found in chronic wounds, indicating
that uncontrolled proteolysis is a characteristic of
retarded healing.18,21,22 Porcine skin wound models
have demonstrated that collagenase has early peak
expression at 1 to 7 days post-wounding, followed by
slow reduction postoperatively with time, with the
sharpest decline occurring after completion of epithe-
lialization.23 The importance of collagen turnover kinet-
ics mediated by MMP expression during wound healing
can be demonstrated in diabetes. It has been shown
in both preclinical and human studies that uncontrolled
hyperglycemia may impair wound healing, and this im-
pairment seems to be directly associated with overex-
pression of MMPs in the wound site.21,24,25 Furthermore,
the utilization of CMT-1 (a chemically modified tetracy-
cline that lacks antimicrobial properties but retains
divalent cation binding and MMP inhibitory activity)
inhibits diabetic connective tissue breakdown in strep-
tozotocin-induced (STZ) diabetic rats by increasing
both steady-state levels of type I procollagen mRNA
and collagen synthesis through mechanism(s) that are
independent of the antibacterial properties of tetracy-
clines.26 In another preclinical study,27 STZ-induced
diabetic rats exhibited cessation of periosteal and
cancellous bone formation. Interestingly, treatment of
diabetic animals with 20 mg/day of minocycline
(a semisynthetic tetracycline) showed increased bone
formation rates comparable to control animals.27 More-
over, growth plate thickness, reduced 43% in diabetic
rats, were preserved in the diabetic animals treated
with minocycline.27 Therefore, inhibition of elevated
levels of specific MMPs during the early phases of tissue
repair may contribute to improved treatment outcomes
by promoting a favorable wound healing in both con-
nective tissue and bone.
The emphasis of this pilot, placebo-controlled,
double-masked clinical investigation was to examine
clinical and laboratory measures of periodontal status
resulting from a 6-month regimen of LDD on postsur-
gical periodontal healing in patients with severe chronic
periodontitis. Clinical, microbiological, and biochemical
parameters were monitored over a 12-month period to




A written informed consent was provided for individuals
willing to participate in this trial who met the inclusion
and exclusion criteria outlined in a protocol approved
by the University of Michigan Institutional Review Board.
Twenty-four subjects (aged 30 to 75 years) diagnosed
with severe chronic periodontitis were enrolled into a
pilot, double-masked, randomized, placebo-controlled,
prospective, parallel arm trial. Pertinent inclusion crite-
ria included patients with at least three teeth in the same
sextant demonstrating both PD and CAL ≥5 mm to
≤12 mm and BOP. The patients also had to have at
least 10 teeth in the functional dentition. Exclusion crite-
ria included chronic treatment (i.e., 2 weeks or more)
with any medication known to affect periodontal status
(i.e., antibiotics or non-steroidal, anti-inflammatory
drugs); antibiotic treatment within 90 days of baseline;
clinically significant or unstable organic diseases; com-
promised healing potential such as connective tissue
disorders or bone metabolic diseases; conditions neces-
sitating antibiotic prophylaxis; females who were preg-
nant (as determined by positive urine pregnancy test at
the prescreening visit) or lactating, or who were of child-
bearing potential and not utilizing birth control or absti-
nence; documented allergies to tetracyclines; heavy
cigarette smokers (≥2 packs/day); active infectious dis-
eases; immunocompromised; or taking steroid medica-
tions. All dental care related to this trial was provided
at no cost to eligible participants.
Study Design
Patients eligible to participate in the study received full-
mouth SRP within 90 days of baseline (surgery). Four-
teen days prior to surgery, subjects were again examined
(screening visit) and inclusion/exclusion criteria reviewed.
In this visit, two prescreened patients did not meet the
inclusion criteria due to healing from SRP. Subjects who
still qualified for the study and required access flap surgery
(AFS) in a minimum of one sextant were randomized to
receive either doxycycline hyclate 20 mg b.i.d.§ or
§ Periostat, CollaGenex Pharmaceuticals, Inc., Newtown, PA.
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line appointment. Six sites were
measured around each tooth in
the mouth (mesio-buccal, buc-
cal, disto-buccal, disto-lingual,
lingual, and mesio-lingual) for
PD, CAL, and BOP. At the same
visit, microbiological parame-
ters and gingival crevicular fluid
(GCF) samples were collected
on teeth assigned to receive
surgery. Examiners (JLB and
MGL) were trained and calibra-
ted to minimize intra-rater (i.e.,
intraexaminer) variability. In
addition, in order to minimize the
impact of inter-rater variability
on the sensitivity of this study,
the same examiner assessed the
same patients for the duration
of the trial.
Surgical procedures were then
performed at baseline (BL) within
14 days of the screening visit
by one surgeon (RG). Patients
returned for follow-up examina-
tions at months 1, 2, 3, 6, 9, and
12 following baseline. Full-mouth
manual probing measurements,
GCF, ICTP levels, and microbio-
logical samples were assessed at
BL and months 3, 6, 9, and 12.
Patients received periodontal main-
tenance therapy at 3, 6, 9, and
12 months following randomization
and periodontal surgery. The study
design is shown in Table 1.
Surgical Procedure
Briefly, following local anesthesia,
treatment sextants received AFS,
which consisted of submarginal
primary incisions (Fig. 1A) and
full-thickness mucoperiosteal flap
reflection. The tooth root surfaces
were debrided, scaled and root
planed using hand and sonic instru-
mentation. Osseous recontouring
(osteoplasty) when indicated was
performed for flap adaptation
(Fig. 1B). The tissues were reposi-
tioned with polyglactin 910 or
silk suture materials (Fig. 1C). The
surgical sites were then covered
with a periodontal dressing. After surgery, patients
Table 1.
Clinical Trial Longitudinal Measures
Month




Full-mouth measurements X X X X X X X
Microbial sampling X X X X X
Urine pregnancy test X X
Surgery X
C-telopeptide level X X X X X X
Maintenance therapy X X X X
Dispense medication X X
Drug accountability X X
Figure 1.
Access flap surgical procedure in a patient administered 20 mg b.i.d. LDD for a period of 6 months,
followed for an additional 6 months. A) Scalloping incisions made to remove the collar of gingival
tissue. B) After flap reflection, the surgical site was debrided followed by SRP and osteoplasty where
necessary. C) Flaps were repositioned utilizing interrupted sutures 4-0 polyglactin 910. Periodontal
dressing was placed and 0.12% chlorhexidine rinses utilized for 14 days. D) LDD-treated sextant 1
year post-LDD therapy + surgery. Note clinical appearance of normal gingival architecture and
healing.
placebo capsules b.i.d. for the 6-month treatment
period. Full-mouth manual clinical measurements
were recorded for all teeth within 2 weeks of the base-
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received pain control medication (an acetaminophen-
containing analgesic) when needed and chemical plaque
control (0.12% chlorhexidine rinse) for 14 days.
Dispensing of Study Medication/Assessment
of Compliance
At the screening visit, qualifying patients were assigned
a code and were then randomized by a computer soft-
ware program to the drug or placebo group. At the
baseline visit, each patient was issued a 3-month sup-
ply of coded study medication including one container
for morning and another for afternoon/evening intake.
Three months following surgery, subjects returned resid-
ual capsules and received an additional 3-month sup-
ply. The residual capsules were counted and retained at
3 and 6 months after baseline. Patient compliance (as
a percentage) with the dosing schedule was recorded.
Microbiological Monitoring
Subgingival plaque samples were collected from the
mesio-buccal sites of each tooth scheduled for surgery
using sterile curets. Samples were then placed in ster-
ile, labeled tubes containing 150 µL TE buffer (10 mM
Tris-HCl, 1 ml EDTA, pH 7.6) and vortexed. Microbial
analyses were performed for the presence and levels
of 40 subgingival pathogens (Table 2) utilizing whole
genomic DNA probes and checkerboard DNA-DNA
hybridization as previously described.28 Signals were
recorded as 0: not detected; 1: <105 cells; 2: ∼105 cells;
3: 105 to 106 cells; 4: ∼106 cells; and 5: >106 cells.
Bone Marker (ICTP) Analysis
Gingival crevicular fluid was collected prior to clinical
measurements. Gingival tissue surrounding the site to
be sampled was dried with gauze, and supragingival
plaque was removed. A sterile methylcellulose strip¶
was gently placed into the mesio-buccal aspect of each
tooth sulcus or pocket until slight resistance was felt
and the GCF collected for 10 seconds. Following col-
lection, the sample was kept on ice for transport to the
laboratory and stored at −80°C. The frozen samples
were then thawed at room temperature and proteins
were eluted through five centrifugations at 3,000 RPM
for 5 minutes with 20 µl phosphate buffered saline
(PBS, pH 7.4) containing 15 nM aprotinin, 1 mM PMSF,
and 0.1% human serum albumin as previously
described.29 GCF ICTP levels were quantified using
radioimmunoassay.#
Gingival Biopsies (Protease Determination)
Six patients (3 from test group, 3 from placebo group)
scheduled to receive two sextants of surgery were eval-
uated for changes in gingival proteinase activity, utiliz-
ing gelatin zymography. Excised tissues from each
treatment sextant were immediately placed on ice and
subsequently frozen (−80°C). Two months later, tissue
samples were harvested from another sextant, during
a subsequent surgery. To prepare tissue extracts, sam-
ples were thawed on ice, homogenized in PBS, and
centrifuged (10,000 × g for 10 minutes at 4°C). Protein
concentration in the extracts was determined using a
protein assay kit** using bovine serum albumin (BSA)
as a standard. The supernatants were diluted with an
equal volume of glycerol and stored at –80°C. Protease
activity was assessed by 12% gelatin zymography††
as previously described.30
Statistical Analyses
Data available for each patient were subjected to an
intent-to-treat analysis and included full-mouth clinical
measurements for three different parameters (PD, CAL,
¶ Periopaper, IDE-Interstate, Amityville, NY.
# DiaSorin, Inc., Stillwater, MN.
** BCA Protein Assay Reagent, Pierce, Rockford, IL.
†† Bio-Rad Laboratories, Hercules, CA.
Table 2.
DNA Probes Used to Examine Subgingival
Plaque Samples
Actinobacillus actinomycetemcomitans Gemella morbillorum
Actinomyces. gerencseriae Leptotrichia buccalis
Actinomyces israelii Neisseria mucosa
Actinomyces naeslundii 1 Propionibacterium acne
Actinomyces naeslundii 2 Prevotella melaninogenica
Actinomyces odontolyticus Peptostreptococcus micros
Tannerella forsythus Porphyromonas gingivalis
Camphylobacter gracilis Prevotella intermedia
Camphylobacter rectus Prevotella nigrescens
Camphylobacter showae Selemonas noxia
Capnocytophaga gingivalis Streptococcus anginosus
Capnocytophaga ochracea Streptococcus constellatus
Capnocytophaga sputigena Streptococcus gordonii
Eikenella corrodens Streptococcus intermedius
Eubacterium nodatum Streptococcus mitis
Eubacterium saburreum Streptococcus oralis
Fusobacterium nucleatum ss nucleatum Streptococcus sanguis
Fusobacterium nucleatum ss Treponema denticola
polymorphum
Fusobacterium nucleatum ss vincentii Treponema socranskii
Fusobacterium periodonticum Veillonella parvula
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and BOP) examined at six sites per tooth.
Sample size determination for this pilot study
was determined from Golub et al.8 using 80%
power for differences expected in a primary
biological outcome measure, the bone resorp-
tion marker, ICTP. The level and prevalence
of 40 species and ICTP levels (pg/site) was
measured from the surgically-treated quad-
rant excluding third molars. Clinical, micro-
bial, and ICTP data were averaged within a
patient and then compared between groups.
In other analyses, data were stratified accord-
ing to baseline PD of 1 to 4, 5 to 6, and
≥7 mm and averaged in a patient and then
across the study population for clinical para-
meters and ICTP levels. Differences between
drug and placebo groups were performed
using the Mann-Whitney test. Differences
with a P value less than 0.05 were considered
significant. Microbiologic data were analyzed
separately for sites receiving AFS + LDD and
AFS + placebo. Mean levels (counts × 105)
for each of 40 species were computed for
each patient in each treatment category at
each visit. Significant differences over time were deter-
mined separately for each treatment category using the
Quade test and the differences between groups were
determined by the Mann-Whitney test. All analyses were
performed using the patient as the unit of analysis.
RESULTS
Calibration
The results for calibration of the examiners revealed the
intraclass correlation coefficients for PD were >0.90
and for CAL measurements were >0.85. Intraexaminer
reliability was determined utilizing the percent agree-
ment within 1 mm between 2 passes and a weighted
kappa statistic. The percent agreement within 1 mm
was ≥95.5% and ≥90% for PD and CAL measurements,
respectively. The weighted kappa statistic was ≥0.92
and ≥0.88 for PD and CAL measurements, respectively.
Demographics
A total of 24 patients entered into the study; 12 were
randomized to the LDD + AFS group and 12 to the
placebo + AFS group. Ten out of 12 patients in the drug
group and 11 out of 12 in the placebo group completed
the study for an overall drop-out rate of 12.5%. One
patient in the LDD group moved away while the other
began administration of a calcium channel blocker that
conflicted with the inclusion criteria. The patient in the
placebo group reported lethargy after capsule intake
and requested exit from the study. At baseline, there
were no statistically significant differences (NS) between
groups regarding age and gender (Table 3). There were
two screening failures at baseline due to changes in PD
Table 3.
Baseline Mean (± SD) Clinical Characteristics
and ICTP
Characteristic Placebo (n = 12) Drug (n = 12) P (Mann-Whitney)
Age
Mean (SD) 53.3 (±9.8) 45.9 (±8.3) NS*
Range 38-71 32-60
% males 67% 67% NS
Tobacco use (n [%])
Current 3 (25%) 5 (41.7%)
Past 6 (50%) 4 (33.3%)
Never 3 (25%) 3 (25%)
BOP (%) 51.3 (±19.3) 56.6 (±15.9) NS
PD (mm) 3.0 (±0.5) 3.1 (±0.3) NS
CAL (mm) 3.8 (±0.8) 4.1(±0.8) NS
ICTP (pg/site) 34.0 (±44.5) 52.0 (±54.2) NS
* Not significant.
following SRP making the individuals ineligible for sur-
gical therapy. Seventy-five percent of subjects reported
past and current use of tobacco in both LDD and
placebo groups (Table 3). In addition, no significant dif-
ferences were noted between the treatment groups with
respect to baseline clinical parameters (PD, BOP, and
CAL) and ICTP levels (Table 3). Levels and distribution
of subgingival species averaged per group at baseline
are displayed in Figure 2. There were no significant dif-
ferences between LDD and placebo groups for any of
the 40 microorganisms analyzed at baseline.
Compliance
The mean overall drug compliance for the LDD group
was 80.6% (range 62% to 105%) while the placebo
group mean was 83.0% (range 18% to 100%); difference
non-significant (NS) between groups. Data also demon-
strated that >90% of patients from both groups were
>70% compliant during the study. Patients had a ten-
dency to be slightly more compliant in the morning
than in the evening (84.1 ± 6.4% versus 79.4 ± 3.5%,
respectively; P >0.05). The subjects also showed trends
of better compliance during the first 3 months of the trial
compared to the second 3 months (84.8 ± 5.0% versus
79 ± 4.3%, respectively; P >0.05). One patient in the
drug group showed low compliance (18%).
Treatment Outcomes: Responses in Clinical
Parameters and ICTP Levels
Pooled surgical sites (all probing depth strata). The
mean per-patient averages in BOP, PD, CAL, and
ICTP from baseline for all surgical sites are shown in
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Figure 3. As expected, both placebo and test groups
demonstrated a statistically significant reduction in PD
compared to baseline (P <0.001); however, no differ-
ences between groups were found. Surgical therapy
resulted in mean CAL gains in both groups (P >0.05).
The LDD group demonstrated a statistically significant
reduction in percentage of BOP sites at 3 and 6 months
compared to baseline (25% to 60%, P <0.05) while in
the placebo group, no statistical significance was found
(∼15%, P >0.05). In addition, the LDD group demon-
strated a decreased but not statistically significant
expression of GCF ICTP levels compared to placebo
during the drug administration period.
Moderate sites (baseline PD 5 to 6 mm). Mean
per-patient averages in BOP, PD, CAL, and ICTP levels
from baseline at surgical sites with a baseline PD of 5
to 6 mm are shown in Figure 4. Consistent with results
from pooled PD strata, there were significant reductions
in PD and gains in CAL compared to baseline for both
drug and control groups, while no statistical difference
between treatments was found although trends for a
drug effect for PD reduction were noted. ICTP levels
were reduced while patients were on LDD therapy, but
a rebound in ICTP levels in the
LDD + AFS group was demon-
strated after patients discontinued
the drug. There was a statistically
significant reduction in the percent
of BOP sites at 3 and 6 months
compared to baseline in the LDD +
AFS group (P <0.05), while no such
effect was seen in patients receiv-
ing placebo capsules (P >0.05).
Both LDD + AFS and placebo +
AFS groups showed comparable
levels in percentage of sites BOP
after the patients discontinued drug
therapy (P >0.05).
Deep sites (baseline PD ≥7 mm).
Figure 5 shows the mean per-
patient averages in BOP, PD, CAL,
and ICTP levels for initially deep
sites. Greater reductions in PD were
noted in this stratum for both
groups. Drug therapy resulted in
more statistically significant reduc-
tion in PD in deep sites compared
to controls (P <0.05) and this dif-
ference was sustained for the dura-
tion of the study. However, no
differences were found between
groups with respect to CAL. In
addition, patients receiving LDD +
AFS showed greater reductions in
ICTP levels compared to placebo +
AFS during the first 6-month
observation period, but no statistical differences were
found (P = 0.09). This difference was also not signifi-
cant when patients discontinued drug therapy. Again,
LDD therapy resulted in a statistical reduction in the
percent of BOP sites (P <0.05) for 6 months while no
such reductions were demonstrated in placebo controls
(P >0.05). However, these differences between groups
were not significant by the end of the trial (P >0.05).
Microbial Outcomes
Comparisons between LDD + AFS and placebo + AFS
were performed utilizing mean microbial DNA counts
of each microorganism averaged per patient and then
per group. When interanalysis was performed, no sta-
tistically significant differences were found for any of the
40 microorganisms tested at any given time point (data
not shown). There was an immediate reduction in red
complex and orange complex species in both drug and
placebo groups after AFS was performed (Fig. 6).
Gelatin Zymography for Proteinase Expression
Five patients (two LDD and three placebo) completed
baseline and 2 months harvest of gingival tissues for
Figure 2.
Mean counts (±SEM) of species sampled at baseline. Microbial analyses were performed at
baseline for the presence and levels of 40 subgingival species utilizing whole genomic DNA probes
and checkerboard DNA-DNA hybridization.The mean count for each species was computed for
each patient and then averaged across patients. Significant differences were determined using the
Mann-Whitney test. SEM = standard error of the means. Colors represent bacteria cluster groupings
described by Socransky et al. 31
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gelatin zymography analysis. After tissue preparation,
zymograms were run in a standard manner, utilizing
commercially available collagenases type IV as a posi-
tive control. Results generated from all patients demon-
strated that a downregulation in gelatinase activity (mean
7.2%; range: 4.9% to 8.5%) in patients receiving adjunc-
tive therapy, while an increase in activity was seen in the
placebo group (mean 5.6%; range: −10.4% to 17.5%).
DISCUSSION
The purpose of the present investigation was to attempt
to unravel biological changes that occur as a result of
a combination of periodontal therapies with antibac-
terial effects (i.e., surgery) and host modulatory effects
(i.e., LDD). The consideration of the bacterial-host
interaction as a basic mechanism for periodontitis
pathogenesis has driven the concept that successful
long-term management of this disease may be depen-
dent upon an effective control of bacterial load in com-
bination with host modulatory therapies. To date, several
bone-sparing agents or host mod-
ulatory drugs have been devel-
oped to control pathways
responsible for periodontal tissue
breakdown such as regulation of
immune32,33 and inflammatory
responses,34-37 excessive pro-
duction of matrix metallopro-
teinases (MMPs),8,10,38 arachidonic
acid metabolites,39-42 and regula-
tion of bone metabolism.43,44
This pilot investigation sought
to evaluate the potential additive
effect of LDD to modulate wound
repair in conjunction with peri-
odontal surgery. The goal was to
explore the clinical, microbial, and
biochemical impact of this drug
on the modulation of wound heal-
ing post-surgically. Following
mechanical therapy in the form of
SRP, patients received access flap
surgery and were randomized to
LDD or placebo groups for 6
months of drug therapy, followed
by a 6-month post-dosing evalu-
ation. As expected, both therapies
led to significant clinical improve-
ments in terms of PD reduction
and CAL gain (Figs. 3, 4, and 5).
Patients in the placebo + AFS
showed probing depth reductions
and clinical attachment level gains
similar to previously reported lon-
gitudinal studies, when the same
therapy was compared.45,46
Tetracycline analogues have been some of the most
extensively investigated host modulatory agents and
specifically, the low dose regimen of doxycycline
hyclate (20 mg b.i.d.).6 Both preclinical and human
clinical data have shown that tetracycline can sup-
press MMPs,8,10,38 which are considered to be primary
enzymes responsible for the destruction of extracellular
matrix macromolecules. Investigators have demon-
strated the effects of adjunctive LDD in conjunction
with supragingival scaling and dental prophylaxis,47-49
and SRP.15,17,50 Caton et al.17 indicated that a 9-month
course of LDD with SRP resulted in statistically signif-
icant improvements in PD reduction and CAL gains
when compared with placebo controls. The effects
were maintained 12 months after initial therapy.50
In this study, clinical efficacy was examined at sites
with baseline PDs of 1 to 4 mm for shallow sulci/pockets
(data not shown), 5 to 6 mm for moderate pockets
(Fig. 4), and ≥7 mm for deep pockets (Fig. 5). This
allowed analysis of the effects of LDD at sites fulfilling
Figure 3.
Effect of LDD or placebo in combination with surgery on clinical parameters and ICTP for all sites
receiving surgery. The shaded background indicates time of drug or placebo administration.The bars
represent per-patient standard errors. P values indicate significant changes over time within a
treatment as determined by the Quade test.
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the criteria for periodontal surgery (i.e., PD ≥5 mm). In
addition, the patients exhibited moderate to severe
horizontal bone loss that is generally not indicated for
traditional regenerative therapy. Therefore, patients
included in this trial exhibited bone loss patterns with
limited treatment options (non-surgical therapy or poc-
ket reduction/elimination surgery). Although the present
investigation was not designed as a definitive clinical
trial, our results suggested a number of intriguing leads.
When LDD was administered in combination with AFS,
a greater probing depth reduction was found in deep
sites of AFS + LDD subjects compared to controls
(Fig. 5, P <0.05). This result was maintained 6 months
after discontinuation of the drug (Fig. 5, P <0.05). How-
ever, no statistically significant differences between ran-
domized groups were noted for CAL in any of the probing
depth strata. There may be potential mechanisms that
explain the PD reduction seen with LDD therapy: LDD
therapy may promote more rapid wound maturation by
inhibiting collagen disruption and
indirectly encouraging collagen for-
mation. Therefore, differences in
timing, quality, and quantity of
wound contraction in the periodon-
tal tissues might have promoted
additional PD reduction in the drug
group.
The results of this study re-
vealed a significant reduction in
percentage of sites exhibiting BOP
when patients were taking LDD as
compared to the placebo group
(Figs. 3, 4, and 5). These results
are in agreement with a previous
investigation,17 where a reduction
in bleeding sites was seen in
patients receiving adjunctive LDD
compared to placebo. By contrast,
Golub et al.9 reported only mini-
mal and non-significant reductions
in gingival inflammation and bleed-
ing index51 with the use of LDD. In
that study,9 the authors suggest
that the improvement in periodon-
tal conditions by LDD therapy
was mainly by inhibiting collagen-
destructive enzymes rather than
affecting microbially-induced in-
flammation.9 However, it is import-
ant to note that the effects of LDD
on BOP in our investigation also
appeared to be independent of
microbial shifts. Therefore, the
effects of LDD on gingival inflam-
mation (i.e., BOP) need to be fur-
ther evaluated. In addition, it should
be noted that both placebo and test groups experi-
enced high BOP frequency at 12 months when deep
probing depths were considered. The reason for that
lies in the fact that the majority of patients were sur-
gically treated only in the tested quadrant. In other
words, remaining pockets after initial therapy on other
quadrants might have served as reservoirs of putative
bacteria that potentially infected the surgically-treated
pockets. These findings have been confirmed by other
investigations which reported that a natural recolo-
nization of pathogenic microorganisms occurs after
periodontal therapy.52-54 Therefore, this aspect could
explain the high frequency of BOP in deep sites as
well as recolonization of putative microorganisms found
in this investigation (e.g., Actinobacillus actino-
mycetemcomitans, Porphyromonas gingivalis, and Pre-
votella intermedia).
LDD + AFS resulted in a decrease in the putative
bone resorption marker ICTP soon after the surgical
Figure 4.
Effect of LDD or placebo in combination with surgery on clinical parameters and ICTP levels
for initial pockets of 5 to 6 mm.The shaded background indicates period of drug or placebo
administration.The bars represent per-patient standard errors. P values indicate significant changes
over time within a treatment as determined by the Quade test.
449
J Periodontol • March 2004 Gapski, Barr, Sarment, Layher, Socransky, Giannobile
therapy at 3 months while placebo controls demon-
strated no change or increases in ICTP levels over the
12-month observation period. ICTP reflects the amount
of organic matrix being disrupted in alveolar bone
(specifically, type I collagen) following osteoclastic
bone resorption. Human histological data have shown
that osteoclastic activity peaks immediately after a
surgical procedure is performed and is then followed
by bone formation.55 Therefore, release of excessive
osteoclastic collagenases (or MMP-13) may have
increased the disruption of collagen type I in bone and
consequently increased ICTP release in the placebo +
AFS group. Golub et al.8 have demonstrated a direct
effect of LDD therapy on the reduction of excessive
MMP-13 followed by a concomitant decline in levels of
collagen degradation fragments. In addition, it has been
demonstrated that the increased circulating concen-
tration of ICTP was most likely produced by action of
MMPs.56 In the same study, cathepsin K-mediated bone
resorption (an osteoclastic cysteine protease) destroyed
ICTP antigenicity, further showing the specificity of
MMPs on the initial disruption of bone collagen.56
Hence, our findings have demon-
strated that utilization of an MMP
inhibitor may have a direct impact
on postsurgical bone turnover.
This result supports the notion that
decreased collagenolytic activity
(via LDD) can reduce bone
resorption and act as a bone-spar-
ing agent. Although these results
are from only a small subset of
patients from our investigation,
these findings should encourage
further exploration of the impact
of host modulatory agents on
bone maintenance.
With regard to the issue of low-
dose antibiotics possibly resulting
in direct microbial shifts, our study
found no statistically significant
differences between drug and con-
trol groups at any time point for
any of the 40 tested species.
These results are in agreement
with previous human trials.57,58 It
should also be noted that only sur-
gical sites were evaluated for
microbial analysis, therefore,
effects of this drug on other sites
are not available. When the data
were analyzed according to bac-
terial complexes as proposed by
Socransky et al.,31 a reduction in
periodontal pathogenic organisms
was found in both groups, and this
outcome was attributed to the effects of periodontal
surgery. These findings are in concordance with recent
reports59,60 that suggest that there is a beneficial effect
of surgery on suppression of periodontal pathogens
by eliminating reservoirs of virulent organisms. How-
ever, effects of continuous administration or cyclical
dosing of LDD + surgery on microbial resistance or
shifts were not evaluated in this study.
This investigation demonstrated no differences
between groups regarding drug compliance. The over-
all compliance was approximately 80% with small ten-
dencies for the patients to be more compliant in the
morning and in the first 3 months of the drug admin-
istration period (NS; P >0.05). In our study, a wide
range of compliance was found (18% to 100%) but it
was also demonstrated that the majority of patients
were reasonably compliant with the 6-month b.i.d. reg-
imen (over 90% were >70% compliant).
CONCLUSIONS
Six-month administration of LDD suggests that there
is an enhanced postsurgical wound healing compared
Figure 5.
Effect of LDD or placebo in combination with surgery on clinical parameters and ICTP for initial
pocket of ≥7 mm.The shaded background indicates time of drug or placebo administration.The bars
represent per-patient standard errors. P values indicate significant changes over time within a
treatment as determined by the Quade test.
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to placebo controls with regard to PD reduction. This
positive effect was most marked in deep sites (≥7 mm),
where the differences in PD reduction were maintained
until the completion of the trial. Reductions in the bone
resorption marker ICTP were also found in patients while
on the drug, suggesting the potential of LDD to act as
a bone-sparing agent. In addition, the percentage of
BOP sites was affected by LDD therapy, but this effect
was only noticeable during the period of the drug admin-
istration. Finally, no significant shifts on the periodon-
tal microbiota beyond that attributable to the effects of
the surgery could be seen with the utilization of LDD.
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